Search results
Results from the WOW.Com Content Network
Meropenem, sold under the brand name Merrem among others, is an intravenous carbapenem antibiotic used to treat a variety of bacterial infections. [3] Some of these include meningitis, intra-abdominal infection, pneumonia, sepsis, and anthrax.
The carbapenems imipenem and meropenem are recommended by the American Thoracic Society and the Infectious Disease Society of America as one of several first-line therapy options for people with late-onset hospital-acquired or ventilator-associated pneumonia, especially when Pseudomonas, Acinetobacter, or extended spectrum beta-lactamase ...
Meropenem/vaborbactam, sold under the brand name Vabomere among others, is a combination medication used to treat complicated urinary tract infections, complicated abdominal infections, and hospital-acquired pneumonia. [1] [2] [3] It contains meropenem, a beta-lactam antibiotic, and vaborbactam, a beta-lactamase inhibitor. [3]
The β-lactam family of antibiotic molecules consists of four groups: penicillins, cephalosporins, carbapenems (such as imipenem, ertapenem, meropenem and doripenem) and monobactams. [19] These antibiotics share common structure and mechanism of action.
Antibiotics that cover Pseudomonas aeruginosa: ... (meropenem, imipenem/cilastatin, ... Vancomycin is used orally for the treatment of C. difficile colitis:
Pseudomonas infection refers to a disease caused by one of the species of the genus Pseudomonas. P. aeruginosa is a germ found in the environment and it is an opportunistic human pathogen most commonly infecting immunocompromised patients, such as those with cancer , diabetes , cystic fibrosis , [ 1 ] severe burns, AIDS , [ 2 ] or people who ...
Vaborbactam [1] is a non-β-lactam β-lactamase inhibitor discovered by Rempex Pharmaceuticals, a subsidiary of The Medicines Company. While not effective as an antibiotic by itself, it restores potency to existing antibiotics by inhibiting the β-lactamase enzymes that would otherwise degrade them.
Narrow-spectrum antibiotics have low propensity to induce bacterial resistance and are less likely to disrupt the microbiome (normal microflora). [3] On the other hand, indiscriminate use of broad-spectrum antibiotics may not only induce the development of bacterial resistance and promote the emergency of multidrug-resistant organisms, but also cause off-target effects due to dysbiosis.